GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DVAX
Dynavax is a biopharmaceutical company known for its adjuvant (vaccine booster) used in many vaccines, including the hepatitis B vaccine. Its stock price depends on the sales of its products and the success of its partners' vaccines using its technology.
Share prices of companies in the market segment - Pharma liver
Dynavax is a biopharmaceutical company known for its adjuvant (vaccine booster) used in many vaccines. We classify it in the Pharma liver sector, and the chart below reflects the dynamics of the entire vaccine technology industry.
Broad Market Index - GURU.Markets
Dynavax Technologies is a biopharmaceutical company that develops and commercializes vaccine adjuvants that enhance immune responses. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
DVAX - Daily change in the company's share price DVAX
The volatility of Dynavax, a biotech developer of vaccine adjuvants, reflects the success of its partners. Change_co measures sensitivity to news about vaccines using its technology. This metric is the basis for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma liver
Dynavax Technologies Corporation is a biotech company. This chart highlights the sector's high volatility. Comparing it to DVAX, which focuses on vaccines, helps assess how sensitive its business is to clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
Dynavax is a biopharmaceutical company specializing in adjuvants—substances that enhance the immune response to vaccines. The vaccine sector is highly volatile. The chart below reflects the average fluctuations in this industry, providing context for evaluating Dynavax shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DVAX
Dynavax is a biotechnology company specializing in the development of vaccines and adjuvants (vaccine boosters). Its year-over-year performance reflects both the commercial success of its existing products and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma liver
Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development of vaccines and adjuvants (substances that enhance the immune response). Its adjuvant is used in many vaccines. The chart shows how its unique technology and the successes of its partners influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dynavax, with its unique vaccine-enhancing technology (adjuvant), is a bet on the future of immunology. Its stock price depends not on the economy, but on the success of its partners and its own hepatitis drug. The chart tells the story of how one key technology can become the basis for many products.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DVAX
The performance of Dynavax, a biopharmaceutical company, depends on the success of its adjuvant. The monthly fluctuations on the chart reflect royalty revenue from the use of its adjuvant in other companies' vaccines (for example, for hepatitis B and COVID-19), as well as news of new partnerships.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company known for its adjuvant CpG 1018, which enhances the immune response of vaccines, including the hepatitis B vaccine. The company's success depends on vaccine sales and new partnerships. The pharmaceutical sector chart provides a general context for assessing the potential of Dynavax's unique adjuvant technology to create more effective vaccines.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies with in-demand vaccines or treatments on the market can be more stable. The chart below shows general market fluctuations. Does Dynavax Technologies demonstrate this stability, or does its status as a biotech make it more volatile?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DVAX
Dynavax Technologies, a biopharmaceutical company specializing in vaccine adjuvants, whose weekly stock price reflects news of partnerships and clinical trials of vaccines using its technology. The success of its partner vaccines directly impacts its stock price.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Dynavax, like other biotech companies specializing in vaccines, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general industry news and how much by specific clinical trial data.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Dynavax Technologies is a biotech company known for its adjuvant, which enhances the effectiveness of vaccines. Its shares follow the rhythm of news about partnerships and developments. The chart will show how independent DVAX's performance is from overall market fluctuations.
Market capitalization of the company, segment and market as a whole
DVAX - Market capitalization of the company DVAX
Dynavax's market capitalization is the financial story of an adjuvant that improves vaccines. The company's stock price reflects the success of its immune-boosting component, which is used in hepatitis B and COVID-19 vaccines. Its performance reflects a bet that its technology will become a key ingredient in next-generation vaccines.
DVAX - Share of the company's market capitalization DVAX within the market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company known for its adjuvant CpG 1018, which enhances the immune response of vaccines, including the hepatitis B vaccine HEPLISAV-B. Its market capitalization reflects the value of this technology. The chart below shows how important the company's adjuvant is for creating more effective vaccines.
Market capitalization of the market segment - Pharma liver
Dynavax Technologies is a biotech company known for its adjuvant, which enhances the effectiveness of vaccines. The chart below shows the overall market capitalization of the entire pharmaceutical sector. Its dynamics provide the backdrop against which Dynavax's technology is being applied in various vaccines.
Market capitalization of all companies included in a broad market index - GURU.Markets
Dynavax is a biotech company known for its adjuvant, which enhances the immune response of vaccines, as well as its own hepatitis B vaccine. Its market capitalization chart tells the story of its "assistant" technology, which has become critical to many new-generation vaccines.
Book value capitalization of the company, segment and market as a whole
DVAX - Book value capitalization of the company DVAX
For Dynavax Technologies, the book value is its production capacity for vaccine adjuvants. The chart below shows the material base for its unique product. Its growth reflects investments in the production of a component that enhances the effectiveness of many vaccines.
DVAX - Share of the company's book capitalization DVAX within the market segment - Pharma liver
Dynavax Technologies is a biotech company developing vaccines and adjuvants (vaccine boosters). Its strength lies in its scientific platform and manufacturing capabilities for its key adjuvant. The share price chart shows how its physical base is critical to the creation of effective vaccines.
Market segment balance sheet capitalization - Pharma liver
Dynavax Technologies develops and commercializes vaccines using its adjuvant (an immune response enhancer). The company has both R&D and manufacturing capabilities. The book value chart helps assess the balance of its intangible assets (patents) and tangible assets (plant).
Book value of all companies included in the broad market index - GURU.Markets
Dynavax's book value lies in its unique vaccine enhancement technology. The company's assets include production facilities for the CpG 1018 adjuvant, which enhances the body's immune response. This provides the raw material needed to make vaccines (including those for hepatitis B and COVID-19) more effective.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DVAX
Dynavax Technologies developed the adjuvant CpG 1018, which enhances the immune response of vaccines. The company's book value is modest. Its market capitalization reflects the value of this adjuvant, which is used in several commercial vaccines (for example, for hepatitis B and COVID-19), and future revenues from its use.
Market to book capitalization ratio in a market segment - Pharma liver
Dynavax Technologies develops and commercializes vaccines using its proprietary adjuvant (immune response enhancer). Its value lies in this technology. The chart shows how the market values the potential of its adjuvant for creating new vaccines compared to its manufacturing and research assets.
Market to book capitalization ratio for the market as a whole
Dynavax Technologies is a biopharmaceutical company known for its adjuvant, which enhances the immune response to vaccines. Its value lies in this unique technology and the royalties generated from its use. The chart shows how the market values this technology platform, a key component of many vaccines.
Debts of the company, segment and market as a whole
DVAX - Company debts DVAX
Dynavax Technologies, a biopharmaceutical company, is using debt to support the commercialization of its vaccine adjuvant and the development of new products. This chart shows how the company is funding the production and marketing of its already approved product, as well as investing in clinical trials of new vaccine candidates.
Market segment debts - Pharma liver
Dynavax Technologies is a biopharmaceutical company known for its adjuvant, which enhances the effectiveness of vaccines. For a company whose product is a key component for other vaccine developers, debt can be used to expand production and finance partnerships. The chart shows how Dynavax's financial strategy supports its unique business model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DVAX
Dynavax Technologies develops and commercializes vaccines using its CpG 1018 adjuvant, which enhances immune responses. This chart shows how the company finances its research and production. It helps assess whether debt poses risks for the company, whose success depends on partnerships and the success of vaccines using its technology.
Market segment debt to market segment book capitalization - Pharma liver
Dynavax Technologies is a biopharmaceutical company known for its adjuvant (an immune response enhancer) used in many vaccines, including the hepatitis B vaccine. This chart shows the overall debt burden in the pharmaceutical industry. It helps assess how the company uses revenue from its core product to fund new developments.
Debt to book value of all companies in the market
Dynavax, whose adjuvant is used in vaccines, has a stable income. This chart shows the overall market leverage, helping to assess the sustainability of its business model. Even if the market is in turmoil, demand for its core product will likely remain strong, ensuring the company's financial stability.
P/E of the company, segment and market as a whole
P/E - DVAX
Dynavax Technologies develops and commercializes vaccines using its proprietary adjuvant, CpG 1018, which enhances the immune response. This chart reflects the commercial success of its hepatitis B vaccine and the potential of its adjuvant. The metric's performance reflects how investors view current sales and future partnerships with other vaccine developers.
P/E of the market segment - Pharma liver
Dynavax Technologies is in the biotech sector, specializing in vaccines. This chart shows the average P/E for this industry. A company's P/E is higher than the industry average, indicating that investors highly value its adjuvant technology and the commercial success of its hepatitis B vaccine, considering it more mature and less risky than the average biotech.
P/E of the market as a whole
Dynavax Technologies owns an adjuvant—a substance that enhances the immune response—used in several commercially successful vaccines, including those for hepatitis B and shingles. This chart shows sentiment in the biotech sector. It helps us understand whether Dynavax is valued as a company with a unique and in-demand technology or whether its success is already fully reflected in its price.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DVAX
Dynavax Technologies is a biopharmaceutical company specializing in the development and commercialization of vaccines. This chart reflects sales expectations for its hepatitis B vaccine and adjuvant, which enhances the efficacy of other vaccines. Future revenue depends on the success of its commercial products and partnerships with other vaccine manufacturers.
%20P%2FE%20DVAX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DVAX&v=1772651853805 "Chart of the company's future (projected) P/E DVAX")
Future (projected) P/E of the market segment - Pharma liver
Dynavax Technologies develops and commercializes vaccines using its adjuvant CpG 1018 to enhance immune responses. This chart compares the company's future profitability expectations with those of the pharmaceutical sector. It shows how confident investors are in the commercial success of its hepatitis B vaccine and the potential of its adjuvant in other vaccines.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772651853863 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Dynavax Technologies is a biopharmaceutical company focused on developing vaccines using its adjuvant, CpG 1018, which enhances the immune response. The company's success depends on partnerships and approvals for new vaccines. Overall market optimism, as illustrated by this chart, is fueling R&D funding in the sector and accelerating the development of new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772651853880 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DVAX
Dynavax Technologies is a biopharmaceutical company specializing in vaccine development. Its primary product is the adjuvant CpG 1018, which enhances the immune response of vaccines, including those for hepatitis B and COVID-19. Revenue depends on sales of these vaccines. This chart shows how vaccine demand and successful partnerships shape the company's cash flow.
Profit of companies in the market segment - Pharma liver
Dynavax Technologies is known for its proprietary adjuvant technology, CpG 1018, which is used to enhance the immune response of vaccines, including its own hepatitis B vaccine, HEPLISAV-B. This chart, which depicts overall profitability in the biotech sector, shows how one technology can be key. The success of Dynavax's adjuvant impacts vaccine effectiveness and the profitability of the entire industry.
Overall market profit
Dynavax Technologies has developed an adjuvant (an immune response enhancer) used in vaccines, including those for hepatitis B and COVID-19. The company receives royalties and sells its product to other pharmaceutical companies. Its business model demonstrates how one key technology can become the basis for several successful products.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DVAX
Dynavax Technologies is a biopharmaceutical company known for its adjuvant CpG 1018, which enhances the immune response of vaccines. The future profit projections you see depend on sales of its own hepatitis B vaccine and the use of the adjuvant by its partners in other vaccines, including COVID-19 vaccines.
%20profit%20of%20the%20company%20DVAX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DVAX&v=1772651854115 "Graph of future (projected) profit of the company DVAX")
Future (predicted) profit of companies in the market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company specializing in vaccine development. Its adjuvant, CpG 1018, is used to enhance the immune response in many vaccines, including the hepatitis B vaccine. This chart shows revenue forecasts for the entire pharmaceutical sector, helping to understand how the company's core technology compares to overall trends in vaccine development.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772651854145 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Dynavax Technologies is a biopharmaceutical company known for its adjuvant, which boosts the immune response of vaccines. Its success depends on partnerships with other vaccine manufacturers. This timing is important because during periods of economic growth, governments and foundations actively fund new vaccine development programs, increasing the potential market for Dynavax's adjuvant.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772651854169 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DVAX
Dynavax Technologies is a biopharmaceutical company specializing in the development of vaccines and adjuvants that enhance immune responses. This multiple, which links market value to sales, reflects the value of its technology. It shows how investors value its adjuvant CpG 1018, which is used in several commercially successful vaccines.
P/S market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company that develops and commercializes innovative vaccines. Its adjuvant, CpG 1018, is used to enhance the immune response in many vaccines, including the hepatitis B vaccine. This chart shows how investors value revenue in the vaccine sector, demonstrating how the market values Dynavax's adjuvant technology and its commercial potential.
P/S of the market as a whole
Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of vaccines. Its primary product is the adjuvant CpG 1018, which enhances the immune response and is used in vaccines against hepatitis B and other viruses. This chart helps understand how the market values companies with unique technology platforms in the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DVAX
Dynavax Technologies is a biopharmaceutical company known for its adjuvant CpG 1018, which enhances the immune response of vaccines. This chart shows how the market values the company based on its future revenue from sales of the adjuvant and the hepatitis B vaccine. It reflects expectations for partnerships with other vaccine manufacturers and increased demand for its products.
%20P%2FS%20DVAX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DVAX&v=1772651854299 "The graph of the company's future (projected) P/S DVAX")
Future (projected) P/S of the market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company specializing in the development and commercialization of vaccines. Its key asset is the adjuvant CpG 1018, which enhances the immune response and is used in vaccines for hepatitis B and other viruses. The company's valuation relative to the sector reflects expectations for the sales of its vaccines and the potential of the adjuvant in future partnerships.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772651854316 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Dynavax Technologies develops and commercializes vaccines using its adjuvant CpG 1018, which enhances the immune response. The company's success depends on partnerships and sales of vaccines, such as the hepatitis vaccine HEPLISAV-B. This market forecast chart reflects investor confidence in the importance of innovation in vaccinology in the fight against infectious diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772651854354 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DVAX
This chart shows the commercial success of two of Dynavax's key products. The company's revenue is generated from both sales of its hepatitis B vaccine, HEPLISAV-B, and sales of its adjuvant, CpG 1018, which enhances the efficacy of other vaccines. This growth reflects the company's strong position in the vaccine and immunology technology market.
Sales of companies in the market segment - Pharma liver
Dynavax Technologies is a commercial biopharmaceutical company specializing in the development and commercialization of vaccines. The company's key asset is adjuvants, which enhance the immune response of vaccines. This chart represents the total revenue of the entire vaccine market, demonstrating the important role played by innovative components like Dynavax's adjuvant.
Overall market sales
Dynavax Technologies Corporation is a biopharmaceutical company specializing in vaccines and adjuvants (vaccine boosters). Its success depends on the commercialization of its products, such as the hepatitis B vaccine, and partnerships. The overall economic situation, shown in this chart, impacts government healthcare budgets and vaccination programs, which are an important market for Dynavax.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DVAX
Dynavax Technologies is a biopharmaceutical company specializing in the development and commercialization of vaccines. Its key product is an adjuvant that enhances the immune response of vaccines, such as those against hepatitis B and COVID-19. This chart reflects analysts' forecasts for demand for vaccines using Dynavax technology.
%20sales%20of%20the%20company%20DVAX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DVAX&v=1772651854546 "Schedule of future (projected) sales of the company DVAX")
Future (projected) sales of companies in the market segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company specializing in vaccine development using its CpG 1018 adjuvant. This forecast chart details expected revenue from their hepatitis B vaccine HEPLISAV-B and from adjuvant sales for other vaccines. This shows which products analysts consider key to the company's growth.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772651854586 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
This graph, reflecting investment in pharmaceutical research, is important for Dynavax Technologies. The company develops adjuvants that enhance the effectiveness of vaccines. Demand for its technology from major pharmaceutical companies depends on their R&D budgets and activity in developing new vaccines, which is stimulated during periods of economic confidence.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772651854615 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DVAX
Dynavax Technologies is a commercial biotechnology company focused on vaccines. This chart shows the profitability of its two key products. Revenue is generated from sales of the hepatitis B vaccine HEPLISAV-B and the adjuvant CpG 1018, which enhances the immune response and is used in other vaccines.
Market segment marginality - Pharma liver
Dynavax Technologies is a biopharmaceutical company focused on vaccine development. Its key asset is the adjuvant CpG 1018, which enhances the immune response and is used in several vaccines, including the hepatitis B vaccine. Profitability depends on sales of these vaccines. This chart shows the average profitability in the pharmaceutical industry, allowing one to assess the success of its technology.
Market marginality as a whole
Dynavax Technologies is a biopharmaceutical company specializing in adjuvants—substances that enhance the immune response to vaccines. Its success depends on partnerships with vaccine developers. This graph, reflecting the overall economic situation, impacts healthcare funding and the development of new vaccines, creating demand for Dynavax's adjuvant technology.
Employees in the company, segment and market as a whole
Number of employees in the company DVAX
Dynavax Technologies Corporation is a biopharmaceutical company focused on vaccine development and commercialization. This chart reflects the size of the team working on adjuvant production (vaccine booster) and commercialization of the hepatitis B vaccine. This growth may be due to expanded production capacity and partnerships with other vaccine developers.
Share of the company's employees DVAX within the market segment - Pharma liver
Dynavax Technologies developed an adjuvant (immune response enhancer) used in the hepatitis B vaccine and other vaccine candidates. This chart shows the company's share of the total number of specialists in the niche field of adjuvant development. This reflects its unique scientific expertise and critical role in creating more effective vaccines.
Number of employees in the market segment - Pharma liver
Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of vaccines using its adjuvant, CpG 1018. This chart reflects employment in the pharmaceutical sector related to liver diseases and vaccines. The growing number of scientists in this field demonstrates the ongoing need for more effective vaccines, confirming the value of Dynavax's technology.
Number of employees in the market as a whole
Dynavax Technologies is a biopharmaceutical company specializing in vaccine and immunotherapy development. Their success hinges on the approval of their adjuvant, CpG 1018, which enhances the immune response. This overall occupancy rate is irrelevant. Their growth is driven by partnerships with other vaccine developers and clinical trial results.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DVAX (DVAX)
Dynavax Technologies is a commercial biopharmaceutical company specializing in vaccines. Its value is based on its adjuvant technology and commercialized products. This chart shows how the market values their unique scientific platform, which improves vaccine efficacy, creating significant intellectual property value.
%20of%20the%20company%20DVAX%20(DVAX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DVAX-DVAX&v=1772651854963 "Chart of market capitalization per employee (in thousands of dollars) of the company DVAX (DVAX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Dynavax Technologies (DVAX) is a biopharmaceutical company known for its adjuvant CpG 1018, which is used in many vaccines (including hepatitis B). Their value lies in this technology platform. This chart helps estimate the market value of their IP.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772651855032 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Dynavax Technologies is a biopharmaceutical company specializing in the development of vaccines and immunotherapies using its adjuvants (immune response enhancers). The company's value lies in its unique technology. This metric reflects the high value the market places on the intellectual property developed by its scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772651855057 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DVAX (DVAX)
Dynavax Technologies is a biotech company known for its adjuvant CpG 1018, which is used in many vaccines (including their own hepatitis B vaccine, HEPLISAV-B). This chart shows the profitability of their hybrid model: revenue from adjuvant and vaccine sales, calculated based on R&D and commercial staff.
%20Chart%20DVAX%20(DVAX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DVAX-DVAX&v=1772651855120 "Company Profit Per Employee (in thousands of dollars) Chart DVAX (DVAX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Dynavax is a "B2B biotech." Their "key" "product" is "HEPLISAV-B" (a "vaccine" for "hepatitis" "B") and "adjuvant" "CpG 1018" (a booster for "other" "vaccines"). This chart shows the benchmark for the "Biotech Sector" (Tools). In this "B2B R&D" sector, the benchmark is *high*. Profit per employee is "generated" by "patents" for the "technology" (adjuvant).
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772651855144 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Dynavax Technologies is a biotech company known for its adjuvant CpG 1018, which is used in many vaccines (including COVID-19). They also market their own hepatitis B vaccine (HEPLISAV-B). This chart shows how profitable the biotech model, generating revenue from both the R&D platform and the product, is compared to the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772651855205 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DVAX (DVAX)
Dynavax Technologies is a commercial biopharmaceutical company focused on vaccines. Its revenue per employee is generated primarily by the adjuvant CpG 1018, used in hepatitis B vaccines and other vaccines. The chart shows the growing sales of this key component, demonstrating its importance for next-generation vaccines.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DVAX-DVAX&v=1772651855223 "Sales chart per company employee DVAX (DVAX)")
Sales per employee in the market segment - Pharma liver
Dynavax Technologies is a biotech company with two key assets: a hepatitis B vaccine (HEPLISAV-B) and the adjuvant CpG 1018, which is used to enhance the immune response in other vaccines (such as COVID vaccines). This chart shows how successful their commercial and manufacturing teams are in monetizing these two products.
Sales per employee for the market as a whole
Dynavax (DVAX) is a biopharmaceutical company that commercialized HEPLISAV-B, a hepatitis B vaccine for adults. They also produce the adjuvant CpG 1018, which is used in other vaccines (including COVID). This chart demonstrates the success of their hybrid model. They generate revenue from both direct sales of their vaccine and from sales of their adjuvant, allowing them to generate significant revenue.
Short shares by company, segment and market as a whole
Shares shorted by company DVAX (DVAX)
Dynavax Technologies is a biotech company whose key commercial product is HEPLISAV-B, a hepatitis B vaccine for adults. They also produce the adjuvant (vaccine booster) CpG 1018. This chart shows bearish bets. Skeptics may doubt the company's ability to significantly increase HEPLISAV-B's market share against the giant GSK or that their adjuvant will find widespread use in other vaccines.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DVAX-DVAX&v=1772651855362 "Short Shares Chart for the Company DVAX (DVAX)")
Shares shorted by market segment - Pharma liver
Dynavax (DVAX) is a biopharmaceutical company known for its adjuvant CpG 1018, which enhances the effectiveness of vaccines (used in the hepatitis B vaccine and some COVID vaccines). This chart shows bets against the pharma sector (liver). Shorts in this segment may reflect doubts about the company's ability to expand the use of its adjuvant to other vaccines.
Shares shorted by the overall market
Dynavax Technologies produces adjuvants—key components that enhance the effectiveness of vaccines. It's an important medical business. However, like many biotechs, DVAX is sensitive to overall market sentiment. When this pessimism indicator rises, investors tend to reduce their positions even in high-quality companies in the sector, fearing a general slowdown.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DVAX (DVAX)
Dynavax Technologies produces the adjuvant CpG 1018, used to enhance vaccines. Its business depends on the success of its partner vaccines. A chart above 70 may reflect approval or strong sales of vaccines containing its adjuvant. A level below 30 may indicate partner failures or a general decline in the vaccine sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DVAX-DVAX&v=1772651855506 "RSI 14 indicator chart for the company's stock DVAX (DVAX)")
RSI 14 Market Segment - Pharma liver
Dynavax Technologies is a biopharmaceutical company known for its adjuvant CpG 1018, which is used to boost the immune response of vaccines (including those for COVID-19 and hepatitis B). This chart measures the overall momentum in the biotech vaccine and hepatitis sector. It helps understand whether DVAX's performance reflects its own success or a broader sector trend.
RSI 14 for the overall market
Dynavax (DVAX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DVAX (DVAX)
Dynavax Technologies (DVAX) is a biopharmaceutical company with two key assets: HEPLISAV-B (a hepatitis B vaccine for adults) and CpG 1018 adjuvant (a vaccine booster). The chart shows the average target price. It reflects analysts' estimates of HEPLISAV-B market share growth and adjuvant revenues to partners worldwide.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DVAX-DVAX&v=1772651855681 "A chart showing analyst consensus forecasts for the expected stock price. DVAX (DVAX)")
The difference between the consensus estimate and the actual stock price DVAX (DVAX)
Dynavax (DVAX) is a biotech whose strength lies in adjuvants. Its CpG 1018 technology (a booster) enhances the effectiveness of vaccines (including its own Heplisav-B for Hepatitis B). This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in the potential of this booster technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DVAX-DVAX&v=1772651855769 "A chart showing the difference between the consensus forecast and the actual stock price. DVAX (DVAX)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Dynavax Technologies is a commercial biopharmaceutical company whose main product is the hepatitis B vaccine (Heplisav-B), as well as the CpG 1018 adjuvant for other vaccines. This chart shows general expectations for the liver pharmaceutical sector. It reflects whether experts believe their vaccine will grow its market share compared to older competitors.
Analysts' consensus forecast for the overall market share price
Dynavax (DVAX) is a biotech company that produces adjuvants for vaccines (e.g., hepatitis B, COVID). This chart of overall market sentiment is important. Optimism = the market is willing to fund R&D (new vaccines). During a recession (pessimism), investors may value DVAX for its stable revenue from existing vaccines.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DVAX
Dynavax (DVAX) is a biotech company with two pillars: a commercial product (the hepatitis B vaccine, HEPLISAV-B) and their adjuvant (CpG 1018), which is used to boost other vaccines (including COVID). This chart is an assessment of their hybrid model. It reflects the commercial success of their own vaccine and the royalties they receive from their adjuvant used by their partners.
AKIMA Market Segment Index - Pharma liver
Dynavax (DVAX) is a biotech and a leader in adjuvants. The company owns a unique technology (CpG 1018) that enhances the immune response of vaccines and also markets its own Hepatitis B vaccine (HEPLISAV-B). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this hybrid (product + technology) model (DVAX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Dynavax is a biopharmaceutical company that markets a hepatitis B vaccine (Heplisav-B) and adjuvants for other vaccines. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercially successful vaccine stacks up against the backdrop of overall economic trends impacting healthcare.
